HC Wainwright & Co. Reiterates Buy on Aquestive Therapeutics, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating for Aquestive Therapeutics, maintaining a $10 price target. Analyst Raghuram Selvaraju continues to support the company's potential.
October 25, 2024 | 11:28 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating for Aquestive Therapeutics, maintaining a $10 price target. Analyst Raghuram Selvaraju continues to support the company's potential.
The reiteration of a Buy rating and maintenance of a $10 price target by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in AQST's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100